CORE Biomedicine Launches with Eisai's Assets to Reshape Cancer Therapy

BOSTON and TOKYO – July 28, 2026 – A new heavyweight has quietly entered the fiercely competitive arena of cancer therapy. CORE Biomedicine, a biotech startup helmed by veteran drug developers, announced its official launch today, armed with a portfolio of preclinical oncology programs licensed exclusively from Japanese pharmaceutical giant Eisai Co., Ltd. The deal, coupled with a simultaneously announced $21 million Series A financing, catapults the company from stealth mode into the spotlight, positioning it as a formidable new player with a novel strategy to outsmart cancer.

The agreement grants CORE exclusive global rights to develop and commercialize multiple early-stage oncology programs originally discovered by Eisai. While the specific targets remain under wraps, the move provides CORE with an instant, diversified pipeline and a powerful springboard for its mission to create a new generation of precision medicines for broader cancer populations.

A New Power Player Emerges from Big Pharma's Pipeline

In the high-stakes world of biotech, a company's foundation is everything. CORE Biomedicine's is built on two pillars: elite leadership and a robust, de-risked asset portfolio. The company was established by a team of seasoned oncology leaders, many of whom have deep ties to Eisai itself. Co-Founder and CEO Dr. Ping Zhu previously served as President and Chief Scientific Officer of H3 Biomedicine, an innovative Cambridge-based discovery subsidiary of Eisai. This shared history and understanding of the licensed programs' potential undoubtedly smoothed the path for this foundational agreement.

"CORE was created to advance an exceptional portfolio of oncology programs grounded in deep cancer biology, precision medicine and lineage therapeutics," said Dr. Douglas McMillin, Co-Founder and Head of Business Development of CORE Biomedicine. "We believe these programs have tremendous potential to address significant unmet medical needs across multiple cancers, and we are committed to advancing them efficiently toward the clinic and ultimately to patients."

This commitment is backed by significant capital. The $21 million Series A round, co-led by UTokyo Innovation Platform Co. and Elikon Venture, provides the necessary fuel to advance these preclinical assets through the critical early stages of development. The participation of a global syndicate of investors from the U.S., Japan, and China underscores the international confidence in CORE's strategy and leadership. This is not just a spin-out; it is a well-capitalized, strategically orchestrated launch designed for rapid progress.

Beyond Genomics: The Scientific Promise of 'Lineage Therapeutics'

For the past decade, precision oncology has been dominated by a genomics-centric approach—identifying specific gene mutations and designing drugs to target them. While this has produced breakthroughs, it only addresses part of the problem. Many cancers lack a clear targetable mutation, and others quickly develop resistance, leading to relapse. CORE Biomedicine is betting its future on what it believes is the next frontier: lineage biology.

The company’s vision is to develop 'lineage therapeutics' that go beyond single genetic alterations to target the fundamental identity of a cancer cell. Every cell in our body has a 'lineage'—a core biological program that dictates its function and identity. Cancer cells hijack and become addicted to these programs for their survival, growth, and resistance to therapy. According to industry experts, this 'lineage plasticity' is a key reason why tumors can evade treatment.

CORE's strategy is to identify these 'hardwired dependencies' and design drugs that selectively sever them. By disrupting the very programs that define a cancer cell's identity, the company aims to create therapies that are not only more effective but also more durable, with the potential to spare normal cells and benefit a much broader patient population. While specific drug targets have not been disclosed, CORE has indicated a focus on challenging luminal cancers, including bladder, pancreatic, stomach, and colorectal cancers, areas with significant unmet needs.

This approach distinguishes CORE from other firms in the space. Its focus is not on cell transplantation but on discovering and developing small molecules or biologics that dismantle the internal machinery of cancer cell identity, representing a sophisticated evolution in the precision medicine paradigm.

The Art of the Deal: Eisai's Strategy of Outsourced Innovation

For an established pharmaceutical giant like Eisai, out-licensing a portfolio of promising internal discoveries might seem counterintuitive. However, the move is a masterstroke of modern R&D strategy, reflecting a growing industry trend of externalizing early-stage innovation to focused, agile partners.

This deal allows Eisai to maximize the potential of its discoveries without diverting resources from its core late-stage assets, such as its blockbuster collaboration with Merck on Lenvatinib. By entrusting these preclinical programs to a dedicated team—one led by a trusted former executive—Eisai de-risks the costly and uncertain early phases of drug development while retaining a significant financial stake in their future success through undisclosed milestone payments and royalties.

This is a well-established playbook for Eisai. The company has a history of strategic partnerships, including a 2022 deal to out-license a splicing modulator discovered by H3 Biomedicine to Roivant Sciences. These agreements demonstrate a sophisticated approach to portfolio management, creating a vibrant ecosystem where internal discoveries can flourish in specialized external environments. For CORE, it provides a priceless head start; for Eisai, it's a low-risk, high-reward bet on outsourced innovation.

Navigating a Crowded Field: CORE's Path Forward

The precision oncology market is a behemoth, projected to exceed $140 billion in 2026 and continue its rapid ascent. Entering this crowded field requires more than just capital; it demands a distinct competitive advantage. CORE's focus on lineage biology provides exactly that, offering a novel scientific angle to tackle the enduring problem of therapeutic resistance.

However, the journey from a preclinical asset to an approved therapy is long and perilous. The company's immediate challenge is to translate its compelling scientific vision into concrete clinical candidates and successfully navigate the rigorous drug development process. The true test will be whether its lineage-targeting drugs can demonstrate superior efficacy and durability in human trials.

With a pipeline of validated assets from a major pharmaceutical partner, a leadership team with a proven track record, and a war chest of fresh capital, CORE Biomedicine is exceptionally well-positioned for the road ahead. The company's launch marks a significant new chapter in the fight against cancer, one where the key to a tumor's destruction may lie in dismantling its very identity.